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40%. This problem is usually addressed by using nitroglycerin
before the baseline measurement to achieve maximal dilation
throughout the study. However, this was not done in the study by
Caiati et al. Thus, the authors’ statement that “vessel size does not
change with respect to the baseline so vessel size cancels out” is
simply untrue, and this is emphasized by a recent study reporting
that such a lack of epicardial coronary dilation response to
adenosine is diagnostic for microvascular disease (5). These two
facts may add up to a substantial underestimation of CFR and, at
least in part, explain why the normal value in this study (2.88) is
considerably lower than that obtained after predilation with
nitroglycerin (3.4) (4) or with other established methods such as
positron emission tomography (3.5–4.0) (6).
Third, the authors use an infusion rate of 0.5 to 2 ml/min of
echo contrast agent, referring to a previous report (2) quoting two
studies (7,8) in which the infusion rate was 2 ml/s. We wonder
whether there might have been a typing error or additional data
justifying a slowing of the infusion rate by a factor 60.
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REPLY
Drs. Kaufmann and Jenni pointed out that a reason for the error in
assessing coronary flow reserve with this novel Doppler method
with adenosine (1) could be both the flow-mediated dilation of the
epicardial vessel during hyperemia and the hyperemia-induced
variation of blood flow velocity profile. In addition, they observed
a large discrepancy between the contrast infusion modalities used
in this recent study and those used in our previous studies.
Regarding the first point, the published data are controversial
and scanty. In fact, an animal study using intravascular echocar-
diography has shown no variation of epicardial coronary vessel size
during intracoronary adenosine (2). In another human study
conducted in patients with and without left main coronary artery
disease, intravenous adenosine did not increase the angiographic
lumen diameter in the mid and distal segments (control 3.39 6
0.85 vs. 3.35 6 0.98 mm after adenosine; percent change 21 6
12%) as compared with the proximal epicardial vessel diameter
(control 3.72 6 0.99 vs. 3.72 6 0.86 mm after adenosine; percent
change 1 6 6%) (3).
Flow-mediated dilation, if any, should not always take place.
Flow-mediated vasodilation is, in fact, impaired both in patients
without increment of flow (in which, of course, no shear stress can
be exerted on the coronary endothelium) and in patients with no
flow-limiting atherosclerosis (4). Therefore, in our study, flow-
mediated vasodilation, if any, should have affected the assessment
of coronary flow reserve only in patients with preserved capacity to
increase flow (no flow-limiting stenosis) and, at the same time,
without overt atherosclerosis of the left anterior descending coro-
nary artery. This refers to only a small percentage of group 1 in our
series. In addition, the data cited by Kaufmann et al. refer mostly
to studies in which an intracoronary bolus of adenosine or papaverine
was administered. In contrast, in our study, intravenous adenosine was
used. It can be hypothesized that a vasodilator agent administered
through the intravenous route can have less effect on the conductance
vessel (only an indirect effect, if any, through increment of flow), as
compared with the intracoronary route (direct effect of bolus and
indirect flow-mediated action) (5). A major impact of flow-mediated
dilation could be hypothesized in studies in which endothelial dys-
function in the absence of coronary artery disease has to be evaluated.
Further studies are needed to shed more light on this issue.
Regarding their second point, the hyperemia-induced blood
flow velocity profile variation is a minor limitation (relatively small
source of error, 12%) of any Doppler method that affects not only
our new noninvasive method but also the intracoronary Doppler
flow wire method.
Regarding their third point, a careful reading of the Methods
sections of this recent study and previous reports would have avoided
any confusion. In fact, there is no contradiction with the previous
experience, because, as correctly specified, only the concentration of
the agent (300 mg/ml) was the same as that in the previous
experience. The modality of administration, however, has changed
radically. Now we use, as reported (1), an infusion through a pump
with an infusion rate of 1 ml/min, where in the past, we manually
injected contrast as a bolus (at ;2 ml/s). The advantage of this new
modality has been addressed in a recent paper of ours (6).
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Routine Elective Cesarean
Section Is Not Justified for
Women With Mechanical Heart Valves
We congratulate Vitale et al. (1) for providing substantive evidence
for a dose-dependent effect on adverse fetal outcome in pregnan-
cies complicated by maternal warfarin therapy. In the United
Kingdom, warfarin embryopathy is rare (2), and recently reported
cases have occurred almost exclusively in women taking large
(.9 mg) doses of warfarin (3). We agree with Vitale et al. (1) that
the small risk of embryopathy (3.4% in their series), which may be
confined to those requiring .5 mg to maintain an adequate
International Normalized Ratio (INR), should not be used as a
justification for recommending that women with prosthetic valves
be managed with heparin throughout their pregnancy, as some
have suggested (4). Indeed, an increased incidence of valve thrombosis
in pregnant women with mechanical valves (albeit mostly older-
generation prostheses in the mitral position) (5), managed with
subcutaneous heparin versus warfarin, has been reported (6). How-
ever, Vitale et al. (1) have highlighted the risks of spontaneous
miscarriage and stillbirth in warfarin-managed pregnancies and have
demonstrated that this too is dose-dependent.
We have two concerns: First is delivery with only brief (two-
day) discontinuation of warfarin therapy. As Vitale et al. pointed
out, the immature fetal liver may not only lead to over-
anticoagulation of the fetus despite a normal INR in the mother,
but also slow clearance of warfarin by the fetus, leading to
continued anticoagulation for up to 10 days after the mother stops
taking warfarin. Although there were no cases of neonatal hem-
orrhage in this series, despite the fact that warfarin was almost
certainly still present in the fetuses at the time of delivery, the
numbers are small and only three babies in the .5 mg group had
reached full term; second is the policy of routine elective cesarean
section at 38 weeks. We do not agree that elective cesarean section
“reduces the risk of perinatal intracranial hemorrhage in the fetus.”
The arguments have been well rehearsed for other maternal
conditions such as autoimmune thrombocytopenic purpura (7) and
hemophilia carriers (8), when there may be a risk of intracranial
hemorrhage in the baby. Indeed, neonatal intracranial hemorrhage
is described after cesarean section in both conditions, and the
current advice is to recommend vaginal delivery (7,8). Pregnancy
increases the risk of valve thrombosis. The time of greatest risk for
venous thrombosis is immediately after delivery, and cesarean
section further increases the risk up to 25-fold (9). We agree with
Elkayam (5), and it is our policy to discontinue warfarin and start
intravenous heparin, which does not cross the placenta and has a
very short half-life, at 36 weeks in preparation for induction of
labor or cesarean section at 38 weeks. We reserve cesarean section
for the usual obstetric indications. Because Vitale et al. (1) state
that “if the patient [on ,5 mg of warfarin] prefers to have vaginal
delivery, intravenous heparin over the last two weeks of gestation
should be offered as an option,” we assume that they deem this to
be a safe alternative. We would suggest that perhaps the emphasis
should be reversed from routine cesarean section to routine vaginal
delivery.
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REPLY
We read with great interest the letter by Nelson-Piercy et al.
regarding our article (1). They gave us the benefit of their
experience.
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